Navigation Links
Halo Therapeutics Receives $500,000 MDA Award to Develop Drug for Duchenne Muscular Dystrophy
Date:11/14/2013

Newton, MA and Tucson, AZ (PRWEB) November 14, 2013

Halo Therapeutics LLC and the Muscular Dystrophy Association (MDA) today announced that $500,000 has been awarded for development of the experimental drug HT-100 as a treatment for Duchenne muscular dystrophy (DMD). The award to Halo, a subsidiary of DART Therapeutics Inc., comes from MDA Venture Philanthropy (MVP), part of MDA's translational research program.

HT-100 is an oral compound designed to combat excessive inflammation and scar formation ("fibrosis") in muscle tissue and to promote healthy muscle fiber regeneration. HT-100 is currently being tested in a multicenter clinical trial in 30 boys and young men with DMD.

DMD is one of nine types of muscular dystrophy, a group of genetic, degenerative diseases primarily affecting voluntary muscles. Caused by mutations in the gene that makes dystrophin (a protein that normally protects muscle cells and keeps them intact), DMD eventually weakens all skeletal muscles (including those used for breathing) and the heart. DMD affects approximately 1 in 3,500 boys with an estimated patient population exceeding 50,000 worldwide.

"We are extremely pleased to have the support of the MDA as we continue development of HT-100," said Marc Blaustein, DART's chief business officer. "This significant award comes at a crucial time, as we have transitioned to clinical testing of HT-100. Ours is a battle against the clock, and this funding from MDA's MVP helps ensure that we can continue rapid progress toward developing HT-100 as a therapy for boys and young men with DMD."

Jane Larkindale, MDA's vice president of research, said, "Excessive inflammation and fibrosis in muscle can interfere with muscle regeneration and can be a significant barrier to certain therapies now in development, such as gene replacement. Drugs like HT-100 have the potential to be used on their own or in conjunction with other treatments. A rigorous review process conducted by MVP has determined that Halo has the capability of taking HT-100 forward in an efficient and safe manner."

About Halo Therapeutics
Halo Therapeutics LLC, is a wholly-owned subsidiary of DART Therapeutics Inc. Based in Newton, Mass., Halo is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for rare fibrotic diseases like Duchenne muscular dystrophy. Founded through a collaboration between patient advocacy organizations and industry veterans, the company is partnering with the clinical community and patients to transform therapeutic options and, by extension, lives. For more information, please visit halotherapeutics.com and dartrx.com.

About MVP
MDA Venture Philanthropy, the drug development arm of the Muscular Dystrophy Association’s translational research program, made the award to Halo. The funding will allow completion of a phase 1b/2a clinical trial of HT-100 in 30 patients with DMD. This type of trial and often additional clinical trials are needed before the U.S. Food and Drug Administration (FDA) can approve a new drug for use in patients.

About MDA
The Muscular Dystrophy Association is the world’s leading nonprofit health agency dedicated to finding treatments and cures for muscular dystrophy, amyotrophic lateral sclerosis (ALS) and other neuromuscular diseases. It does so by funding worldwide research; by providing comprehensive health care services and support to MDA families nationwide; and by rallying communities to fight back through advocacy, fundraising and local engagement. Visit mda.org and follow us at Facebook facebook.com/MDAnational and Twitter @MDAnews.

  • MDA -

Read the full story at http://www.prweb.com/releases/2013/11/prweb11332835.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. The Prostate Cancer Therapeutics Market 2013-2023
2. Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline
3. CFAST Sparks Pathways for Developing New Therapeutics for Unmet Patient Needs
4. Global NASH Therapeutics Market to Record 30% CAGR Through 2017, According to GlobalData Report Published at MarketPublishers.com
5. Global Melanoma Therapeutics Market 2012-2016
6. Fulgent Therapeutics Announces That CAP (College of American Pathologists) Has Accredited Their Clinical Laboratory
7. Multiple Myeloma Therapeutics Future Discussed in In-demand MP Advisors Report Published at MarketPublishers.com
8. American Assoc. for Cancer Research co-hosts conference on molecular targets and cancer therapeutics
9. Global Dermatophytic Onychomycosis Therapeutics Market 2012 - 2016: Worldwide Industry Latest Market Share, Growth, Size, Trends, Strategy And Forecast Research Report
10. Global Huntington’s Disease Therapeutics Industry
11. Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2017)... ... , ... Ecommerce sales have grown every year since the 1990’s, with 2016 ... consequences of rapid innovation and growth are often neglected in the name of progress. ... and individual’s job to give something back to the planet that provides the resources ...
(Date:4/22/2017)... Capistrano (PRWEB) , ... April 22, 2017 , ... The San Juan Capistrano summer ... released a parenting report outlining the need for summer camps to provide physical activities for ... Importance of Physical Activity In Summer Camps , With an increase in specialty camps that ...
(Date:4/21/2017)... MA (PRWEB) , ... April 21, 2017 , ... ... University professor Christopher Salas-Wright finds that youth violence is declining—and at noteworthy rates. ... the relative proportion of young people involved in violence in the United States. ...
(Date:4/21/2017)... ... April 21, 2017 , ... Young Asset Protection, an insurance ... throughout the greater Pittsburgh metropolitan region, is joining forces with the local chapter ... differently-abled children. , Variety the Children’s Charity is a national organization dedicated to ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... announced it’s been named Agency of Record (AOR) for Theravent, Inc. , ... eliminate snoring. Theravent’s parent company, Foundation Consumer Healthcare, is now working to expand ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... DUBLIN, Ohio , April 18, 2017  Cardinal ... its Non-GAAP 1 fiscal 2017 earnings per share ... 2018 and 2019.  This is in conjunction with this ... Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... EPS from continuing operations will be at the bottom ...
(Date:4/18/2017)... DIEGO , April 18, 2017  Astute Medical, ... a case series to be presented at the 2017 ... which begins today and continues through April 22. Physicians ... IGFBP-7 , used to assess risk for acute kidney ... decompensated heart failure (ADHF). Elevated levels ...
(Date:4/18/2017)... -- Spero Therapeutics, LLC, a biopharmaceutical company founded to develop ... present preclinical data supporting the use of SPR741 combination ... infections at the 27th European Congress of Clinical Microbiology ... Vienna, Austria . ... "Our ongoing preclinical research helps ...
Breaking Medicine Technology: